Abstract:Variation in blood pressure levels display circadian rhythms. Complete 24‐hour blood pressure control is the primary goal of antihypertensive treatment and reducing adverse cardiovascular outcomes is the ultimate aim. This is an update of the review first published in 2011. To evaluate the effectiveness of administration‐time‐related effects of once‐daily evening versus conventional morning dosing antihypertensive drug therapy regimens on all‐cause mortality, cardiovascular mortality and morbidity, total adverse events, withdrawals from treatment due to adverse effects, and reduction of systolic and diastolic blood pressure in people with primary hypertension. We searched the Cochrane Hypertension Specialised Register via Cochrane Register of Studies (17 June 2022), Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 6, 2022); MEDLINE, MEDLINE In‐Process and MEDLINE Epub Ahead of Print (1 June 2022); Embase (1 June 2022); ClinicalTrials.gov (2 June 2022); Chinese Biomedical Literature Database (CBLD) (1978 to 2009); Chinese VIP (2009 to 7 August 2022); Chinese WANFANG DATA (2009 to 4 August 2022); China Academic Journal Network Publishing Database (CAJD) (2009 to 6 August 2022); Epistemonikos (3 September 2022) and the reference lists of relevant articles. We applied no language restrictions. We included randomised controlled trials (RCTs) comparing the administration‐time‐related effects of evening with morning dosing monotherapy regimens in people with primary hypertension. We excluded people with known secondary hypertension, shift workers or people with white coat hypertension. Two to four review authors independently extracted data and assessed trial quality. We resolved disagreements by discussion or with another review author. We performed data synthesis and analyses using Review Manager Web for all‐cause mortality, cardiovascular mortality and morbidity, serious adverse events, overall adverse events, withdrawals due to adverse events, change in 24‐hour blood pressure and change in morning blood pressure. We assessed the certainty of the evidence using GRADE. We conducted random‐effects meta‐analysis, fixed‐effect meta‐analysis, subgroup analysis and sensitivity analysis. We included 27 RCTs in this updated review, of which two RCTs were excluded from the meta‐analyses for lack of data and number of groups not reported. The quantitative analysis included 25 RCTs with 3016 participants with primary hypertension. RCTs used angiotensin‐converting enzyme inhibitors (six trials), calcium channel blockers (nine trials), angiotensin II receptor blockers (seven trials), diuretics (two trials), α‐blockers (one trial), and β‐blockers (one trial). Fifteen trials were parallel designed, and 10 trials were cross‐over designed. Most participants were white, and only two RCTs were conducted in Asia (China) and one in Africa (South Africa). All trials excluded people with risk factors of myocardial infarction and strokes. Most trials had high risk or unclear risk of bias in at least two of several key criteria, which was most prominent in allocation concealment (selection bias) and selective reporting (reporting bias). Meta‐analysis showed significant heterogeneity across trials. No RCTs reported on cardiovascular mortality and cardiovascular morbidity. There may be little to no differences in all‐cause mortality (after 26 weeks of active treatment: RR 0.49, 95% CI 0.04 to 5.42; RD 0, 95% CI −0.01 to 0.01; very low‐certainty evidence), serious adverse events (after 8 to 26 weeks of active treatment: RR 1.17, 95% CI 0.53 to 2.57; RD 0, 95% CI −0.02 to 0.03; very low‐certainty evidence), overall adverse events (after 6 to 26 weeks of active treatment: RR 0.89, 95% CI 0.67 to 1.20; I2 = 37%; RD −0.02, 95% CI −0.07 to 0.02; I2 = 38%; very low‐certainty evidence) and withdrawals due to adverse events (after 6 to 26 weeks active treatment: RR 0.76, 95% CI 0.47 to 1.23; I2 = 0%; RD −0.01, 95% CI −0.03 to 0; I2 = 0%; very low‐certainty evidence), but the evidence was very uncertain. Due to the very limited data and the defects of the trials' designs, this systematic review did not find adequate evidence to determine which time dosing drug therapy regimen has more beneficial effects on cardiovascular outcomes or adverse events. We have very little confidence in the evidence showing that evening dosing of antihypertensive drugs is no more or less effective than morning administration to lower 24‐hour blood pressure. The conclusions should not be assumed to apply to people receiving multiple antihypertensive drug regimens. Key messages — There may be little to no difference in death for any reason between taking blood pressure‐lowering medicines in the morning or evening, but we have no confidence in the results. The difference in unwanted effects was not known. — Taking blood pressure‐lowering medicines in the evening may give slightly better bl -Abstract Truncated-

Optimal Time to Administer Once-Daily Oral Cardiovascular Agents: Evidence Based on Randomized Clinical Trials in the Last Ten Years

Optimal Time to Take Once-Daily Oral Medications in Clinical Practice.

Evening versus morning dosing regimen drug therapy for hypertension

Circadian chronotherapies of coronary heart disease and its biological risk factors: A United States Prescribers' Digital Reference-based review

Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) study

Evidence-Based Optimization Research on the Timing of Traditional Chinese Medicine Intervention for Coronary Heart Disease: Trial Design and Thinking

Efficacy and Tolerability of Long-Acting Nifedipine GITS/OROS Monotherapy or Combination Therapy in Hypertensive Patients

Evening dosing versus morning dosing of antihypertensive medications for nocturnal hypertension: a systematic review and meta-analysis of 107 randomized controlled trials

A Systematic Review of the Efficacy and Safety of Aspirin When Delivered at Different Medication Times for the Primary and Secondary Prevention of Cardiovascular and Cerebrovascular Diseases

Effect of optimized administration time of amlodipine besylate tablets on the morning blood pressure surge in elderly hypertensive patients

Study of the effects on blood pressure for patients with patients with non-dipper hypertension by different administration time

Study of restraining effect of chronotherapeutics on morning blood pressure surge in elderly patients with hypertension

Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?

Analysis on Method for Drug Delivery at Selected Time

Time-Dependent Effects of Physical Activity on Cardiovascular Risk Factors in Adults: A Systematic Review.

Advances in clinical studies of oral anticoagulation

Update on trials examining effects of night-time blood pressure lowering drug treatment on prevention of cardiovascular disease

Clinical comprehensive evaluation of direct oral anticoagulants for patients with atrial fibrillation in China

The Association of Dietary Vitamin Intake Time Across a Day With Cardiovascular Disease and All-Cause Mortality

Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants

Effects of Message Framing and Time Discounting on Health Communication for Optimum Cardiovascular Disease and Stroke Prevention (EMT-OCSP): a protocol for a pragmatic, multicentre, observer-blinded, 12-month randomised controlled study